John S. Bevan

4.5k total citations
73 papers, 2.8k citations indexed

About

John S. Bevan is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Epidemiology. According to data from OpenAlex, John S. Bevan has authored 73 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Endocrinology, Diabetes and Metabolism, 27 papers in Surgery and 13 papers in Epidemiology. Recurrent topics in John S. Bevan's work include Pituitary Gland Disorders and Treatments (44 papers), Growth Hormone and Insulin-like Growth Factors (29 papers) and Adrenal and Paraganglionic Tumors (21 papers). John S. Bevan is often cited by papers focused on Pituitary Gland Disorders and Treatments (44 papers), Growth Hormone and Insulin-like Growth Factors (29 papers) and Adrenal and Paraganglionic Tumors (21 papers). John S. Bevan collaborates with scholars based in United Kingdom, France and United States. John S. Bevan's co-authors include C. W. BURKE, Prakash Abraham, Jonathan Webster, Alison Avenell, Christopher B. T. Adams, Margaret M. Esiri, Wendy Watson, Susan McGeoch, Stephan Petersenn and Sam Philip and has published in prestigious journals such as The Lancet, Endocrine Reviews and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

John S. Bevan

69 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John S. Bevan United Kingdom 29 2.5k 1.0k 554 337 315 73 2.8k
Achille Stevenaert Belgium 30 1.6k 0.6× 985 0.9× 635 1.1× 431 1.3× 526 1.7× 98 2.8k
Brooke Swearingen United States 37 3.6k 1.5× 1.7k 1.7× 879 1.6× 271 0.8× 790 2.5× 96 4.6k
Vivien Bonert United States 21 2.0k 0.8× 887 0.9× 356 0.6× 101 0.3× 235 0.7× 43 2.2k
Raymond V. Randall United States 26 1.7k 0.7× 565 0.5× 467 0.8× 97 0.3× 462 1.5× 57 2.2k
Bernardo Liberman Brazil 21 1.2k 0.5× 790 0.8× 318 0.6× 53 0.2× 207 0.7× 75 1.8k
João Paulo Almeida United States 24 1.2k 0.5× 891 0.9× 945 1.7× 113 0.3× 488 1.5× 122 2.0k
Sylvie Salenave France 34 2.3k 0.9× 1.3k 1.2× 432 0.8× 170 0.5× 335 1.1× 83 3.6k
Lisa B. Nachtigall United States 27 1.3k 0.5× 470 0.5× 380 0.7× 110 0.3× 292 0.9× 68 2.3k
Charles F. Abboud United States 21 1.4k 0.6× 595 0.6× 333 0.6× 106 0.3× 347 1.1× 44 1.6k
Marcello D. Bronstein Brazil 38 5.6k 2.3× 2.4k 2.3× 1.2k 2.2× 440 1.3× 739 2.3× 158 6.2k

Countries citing papers authored by John S. Bevan

Since Specialization
Citations

This map shows the geographic impact of John S. Bevan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John S. Bevan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John S. Bevan more than expected).

Fields of papers citing papers by John S. Bevan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John S. Bevan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John S. Bevan. The network helps show where John S. Bevan may publish in the future.

Co-authorship network of co-authors of John S. Bevan

This figure shows the co-authorship network connecting the top 25 collaborators of John S. Bevan. A scholar is included among the top collaborators of John S. Bevan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John S. Bevan. John S. Bevan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pereira, Olívia R., et al.. (2014). Factors Contributing to High Levothyroxine Doses in Primary Hypothyroidism: An Interventional Audit of a Large Community Database. Thyroid. 24(12). 1765–1771. 27 indexed citations
2.
Giustina, Andrea, John S. Bevan, Marcello D. Bronstein, et al.. (2014). Sagit©: A Novel Clinician-Reported Outcome for Managing Acromegaly in Clinical Practice. Value in Health. 17(7). A355–A355. 3 indexed citations
3.
Bevan, John S.. (2013). Pituitary incidentaloma. Clinical Medicine. 13(3). 296–298. 5 indexed citations
4.
Muir, Kenneth, et al.. (2010). Radioiodine for Graves' disease: what do patients really think?. PLoS Biology. 22(6). e3002664–e3002664. 1 indexed citations
5.
Pereira, Olívia R. & John S. Bevan. (2008). Preoperative assessment for pituitary surgery. Pituitary. 11(4). 347–351. 15 indexed citations
6.
Svensson, Johan, Nick Finer, Pierre Bouloux, et al.. (2007). Growth hormone (GH) replacement therapy in GH deficient adults: Predictors of one-year metabolic and clinical response. Growth Hormone & IGF Research. 17(1). 67–76. 22 indexed citations
7.
Bevan, John S.. (2005). The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly. The Journal of Clinical Endocrinology & Metabolism. 90(3). 1856–1863. 192 indexed citations
8.
Abraham, Prakash, et al.. (2005). Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database of Systematic Reviews. CD003420–CD003420. 31 indexed citations
9.
Farooqi, I. Sadaf, et al.. (1999). The Therapeutic Value of Somatostatin and Its Analogues. Pituitary. 2(1). 79–88. 6 indexed citations
10.
Walmsley, D., N A Matheson, Sebastian Ewen, R. L. HIMSWORTH, & John S. Bevan. (1995). Nesidioblastosis in an Elderly Patient. Diabetic Medicine. 12(6). 542–545. 20 indexed citations
11.
Bevan, John S., et al.. (1992). Dopamine Agonists and Pituitary Tumor Shrinkage. Endocrine Reviews. 13(2). 220–240. 336 indexed citations
12.
Seckl, Jonathan R., Stafford L. Lightman, David B. Dunger, et al.. (1990). Vasopressin antagonist in early postoperative diabetes insipidus. The Lancet. 335(8702). 1353–1356. 15 indexed citations
13.
Bevan, John S., C. W. BURKE, Margaret M. Esiri, et al.. (1989). STUDIES OF TWO THYROTROPHIN‐SECRETING PITUITARY ADENOMAS: EVIDENCE FOR DOPAMINE RECEPTOR DEFICIENCY. Clinical Endocrinology. 31(1). 59–70. 32 indexed citations
14.
Cohen, David, John S. Bevan, & Christopher B. T. Adams. (1989). The Presentation and Management of Pituitary Tumours in the Elderly. Age and Ageing. 18(4). 247–252. 37 indexed citations
15.
Webster, Jonathan, J. Ham, John S. Bevan, & M. F. Scanlon. (1989). Growth factors and pituitary tumors. Trends in Endocrinology and Metabolism. 1(2). 95–98. 8 indexed citations
16.
Bevan, John S. & C. W. BURKE. (1989). PERIFUSION STUDIES OF BROMOCRIPTINE‐TREATED AND UNTREATED MACROPROLACTINOMAS: EFFECTS OF DOPAMINE, BROMOCRIPTINE AND TRH. Clinical Endocrinology. 30(6). 667–680. 4 indexed citations
17.
Bevan, John S., et al.. (1989). Development of an invasive macroprolactinoma: a possible consequence of prolonged oestrogen replacement. Case report. BJOG An International Journal of Obstetrics & Gynaecology. 96(12). 1440–1444. 13 indexed citations
18.
Bevan, John S., C. W. BURKE, Margaret M. Esiri, & Christopher B. T. Adams. (1987). Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. The American Journal of Medicine. 82(1). 29–32. 61 indexed citations
19.
Bevan, John S., Christopher B. T. Adams, C. W. BURKE, et al.. (1987). FACTORS IN THE OUTCOME OF TRANSSPHENOIDAL SURGERY FOR PROLACTINOMA AND NON‐FUNCTIONING PITUITARY TUMOUR, INCLUDING PREOPERATIVE BROMOCRIPTINE THERAPY. Clinical Endocrinology. 26(5). 541–556. 69 indexed citations
20.
Bevan, John S., Martin Gough, M. D. G. Gillmer, & C. W. BURKE. (1987). CUSHING'S SYNDROME IN PREGNANCY: THE TIMING OF DEFINITIVE TREATMENT. Clinical Endocrinology. 27(2). 225–233. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Achille Stevenaert Breakdown of academic impact, for papers by Brooke Swearingen Breakdown of academic impact, for papers by Vivien Bonert Breakdown of academic impact, for papers by Raymond V. Randall Breakdown of academic impact, for papers by Bernardo Liberman Breakdown of academic impact, for papers by João Paulo Almeida Breakdown of academic impact, for papers by Sylvie Salenave Breakdown of academic impact, for papers by Lisa B. Nachtigall Breakdown of academic impact, for papers by Charles F. Abboud Breakdown of academic impact, for papers by Marcello D. Bronstein
Rankless by CCL
2026